MGMT and pituitary tumor: These findings suggest that aggressive SPAs with low MGMT expression could be potential candidates for treatment with temozolomide (115); however, a recent survey performed by the European Society of Endocrinology showed that, in general, silent pituitary tumors were less likely to respond to temozolomide than secreting pituitary tumors, independent of MGMT expression status (109).